Gastrointestinal damage (comprising ulceration and hmmorrhage) is amongst the most prevalent and serious side-effects associated with the use of non-steroid anti-inflammatory (NSAI) drugs (Rainsford 1975a , Cooke 1976) . This side-effect effectively limits the safe use of these drugs. In recent years there have been several attempts to produce drugs with low gastric toxicity (e.g. Sofia et al. 1975 , Rainsford & Whitehouse 1976 which in itself is recognition of the need for nonulcerogenic NSAI drugs. Time is the usual criterion employed to establish if an NSAI drug with apparently low gastrointestinal toxicity (assessed in animal trials) will perform similarly in the clinic. Long-term clinical experience is really an unsatisfactory way of establishing ulcerogenic activity. That it takes so long to learn whether or not a particular NSAI drug will have reasonable so-called 'gastric tolerance' is a poor reflection on (1) the predictive value of existing assays of gastrointestinal damage in animals (and also in humans), and (2) lack of information on the interactions between NSAI drugs and the normal compared with the diseased gastrointestinal mucosm (i.e. in arthritic conditions).
Proceduresfor Assessing Gastrointestinal Damage Current procedures for assessing gastrointestinal damage in animals involve either simple visual observations and histological examination of the gastrointestinal mucosa, or the measurement of 51Cr in the feces from labelled red blood cells (the so-called radiochromium 'blood-loss' technique) in normal (healthy) animals. The problem is that these procedures are probably totally inadequate for testing new drugs.
In recent years the radiochromium 'blood loss' method has been applied to animal testing (Menasse-Gdynia & Krupp 1974) as a simple adaptation of the technique which has been employed for over 20 years in humans (Gray & Sterling 1950) . Unfortunately, there is little appreciation of the serious limitations of this technique and the interpretation of data from this method. Most important of all is the fact that radiochromium from labelled red cells can be excreted in the bile (Stephens & Laurenson 1969) and that salicylates (and some other NSAI drugs) are capable of stimulating the flow of bile into the intestine (Schmidt et al. 1938 , Bullough et al. 1970 . Hence, this method could lead to an apparent increase of 51Cr into the intestinal tract and so may not represent true blood loss. Support for this suggestion comes from studies which have shown that that 51Cr content in feces of individuals who have taken aspirin is unrelated to gastrocamera observations of damage in the stomach of these same individuals (Kuiper et al. 1969 ), or to the quantity of radiochromium in the faeces from injected 5"Cr-labelled albumin (Beeken 1967) . Moreover, the loss of blood assessed by the 51Cr blood loss technique may bear little or no relationship to the presence of ulcers or the quantity of mucosal damage (Rainsford 1975a) . It would seem, therefore, only possible to assess accurately the effects of NSAI drugs on the gastrointestinal mucosa by direct visual observations, i.e. by gastroscopy in humans, or from post-mortem examination of animals.
Some authors have attempted to compare the data obtained from animal studies of the gastric damage of NSAI drugs with that of the therapeutic activity (from the various anti-inflammatory assays) and thereby to derive a therapeutic ratio for these drugs. This involves a simple numerical comparison of the dosage ratios (ED50) for the appearance of gastric damage with that for antiinflammatory effects (Menasse-Gdynia & Krupp 1974) . While such a procedure appears an attractive method for predicting the relative gastric safety of different NSAI drugs, in practice it would seem to have little value. Apart from the difficulties of being unable to use the variable data from some assays of anti-cedemic or anti-arthritic activity in animals to predict doses in humans at which clinical effectiveness is achieved (i.e. antiinflammatory or anti-rheumatic activity), there are real difficulties with the sensitivity in measurement of gastric mucosal damage to laboratory animals (Rainsford 1977a ). In many respects this is a reflection of the lack of information on the type and degree (or severity) of damage to the gastric and intestinal mucosxe in diseased state(s). Attempts to extrapolate the gastrointestinal lesion data obtained from normal animals to the human pathological situations is unreal because the effects of NSAI drugs in the diseased state (i.e. arthritis) may be different from those in healthy individuals.
The Role ofStress States in Gastrointestinal Damage by NSAI Drugs Many arthritic patients who take NSAI drugs are under considerable (as yet unspecified) forms of stress. Stress conditions lead to marked (adaptative) changes in metabolism which may affect the capacity to resist injury induced by NSAI drugs in the gastrointestinal tract.
It is well known that psychological stress (e.g. excessive emotion, tension or anxiety states) will induce the development of acute and chronic ulceration or hxemorrhage (Menguy 1972 , Clarke et al. 1972 ). Among the best examples of the effects of psychological stress are seen in the development of gastric ulcers in soldiers under the stress of combat conditions, e.g. in Vietnam (Bowen & Fleming 1974) . Since stress conditions can cause gastric ulceration and haemorrhage, it seems that drugs which have a propensity to induce gastric damage could interact with stress to produce a potentially 'explosive' situation in individuals under stress.
Apart from the direct effects of psychological or 'disease' stress conditions on the gastrointestinal mucosa there are possibly indirect effects on systemic metabolism (especially in the liver).
Amongst other things the detoxification of drugs may be affected and the amount of albumin binding of NSAI drugs reduced, so leading to marked changes in the biodistribution of these drugs (Morton & Chatfield 1970 , Whitehouse & Beck 1973 . This could contribute to the marked increase in gastrointestinal side-effects noted in arthritic patients (Sun et al. 1974 ).
Models ofNSAI Drug-induced Gastric Ulcerogenesis
To test the hypothesis that stress conditions increase the sensitivity of the gastric mucosa to damage by NSAI drugs the effects of these drugs were studied in animals which had been exposed briefly to reproducible stress conditions (e.g. exposure to cold or restraint). The results were compared with the effects of these drugs in normal (i.e. non-stressed) animals. The stress conditions used are known to reproduce some of the physiological responses of psychologic stress states in the stomach (Ackerman 1975) . The conditions were sufficiently mild in effect so that no damage was observed in the stomach of animals exposed to the stress conditions alone. The results showed that there was a marked increase in the amount of gastric damage and hemorrhage induced by NSAI drugs given orally to stressed compared with that in non-stressed animals (Rainsford 1975b) . Moreover, the effects in stressed animals have been shown to be sufficiently severe to cause the development of gastric ulcers (Rainsford 1977b) . This is a significant finding since gastric ulcers per se are rarely observed in animals following single or repeated oral administration of high therapeutic doses of aspirin (and many other NSAI drugs), only superficial mucosal (focal) damage being observed. Oral administration of known non-ulcerogenic analgesic drugs, e.g. paracetamol and dextropropoxyphene, did not cause development of gastric mucosal damage in physically stressed animals (Rainsford 1975b (Rainsford , 1977c . Hence the effects are specific for those NSAI drugs with previously known ulcerogenic potential. The synergistic effects of NSAI drugs and stress on the gastric mucosa are specifically confined to the acid-secreting region (fundic) mucosa (and occasionally nearby antral region) (Rainsford 1977b) . This synergy has been observed in a variety of laboratory animals (such as rats, guinea-pigs and pigs) and the same responses are evident in both sexes (Rainsford 1975b (Rainsford , 1977c . Moreover, no damage has been observed in the intestinal tract of these animals. These results show that the combined treatment with NSAI drugs and stress produces very specific effects. The mechanism of NSAI drug-induced gastric ulcerogenesis in this model is currently being investigated. Studies to date with aspirin show that of the principal stress axes likely to be implicated in the development of gastric damage, the vagal-parasympathetic system is principally involved (Rainsford 1976) . Also, increased histamine activity (presumably following release of histamine from intramucosal stores) appears-to be implicated ( Rainsford 1976, and unpublished observations) .
Extensive damage is observed in the parietal cells located deep in the gastric mucosa of aspirin plus stress-treated rats (Rainsford 1977b) . Also, extensive disruption of pepsinogen-secreting (zymogen) cells occurs at the base of the gastric pit; an effect which is not normally seen in the gastric mucosa of animals given aspirin alone (Rainsford 1975c) . Clearly, this combined damage to both acid-and pepsin-secreting cells in the gastric mucosa provides evidence of their role in autodigestion processes in the initiation of the pre-ulcer state.
While aspirin causes gastric ulceration in physically-stressed animals, this drug does not induce more gastric damage in adjuvant-induced polyarthritic rats compared with the damage observed in normal healthy animals (Rainsford & Whitehouse 1976 , Rainsford 1977d . In contrast, indomethacin produces more intestinal damage in adjuvant arthritic rats compared with normal (healthy) rats (DiPasquale & Welaj 1973) . The results show that there may be marked variation in the development of gastrointestinal side-effects according to the type and severity of the stress conditions and NSAI drug taken.
Interactions of NSAI drugs with the Gastric Mucosa It is apparent from these studies that there is, a priori, a principal interaction between NSAI drugs and the acid-secreting regions or the nearby acidbathed areas of the mucosa in the stomach. Evidence is accumulating to support the proposition that the parietal cell may be a principal site of action of aspirin and NSAI drugs in the initiation of gastric mucosal damage (Rainsford & Brune 1976) . This could be due to an acceleration of the uptake and subsequent entrapment of the drug anions into the parietal cells (Rainsford & Brune 1976) according to the well-established principles of the absorption of acidic drugs in the stomach (Korolkovas 1970) . Recent autoradiographic and biochemical studies have shown that there is selective uptake of acidic drugs (e.g. salicylic acid) but not non-acidic NSAI drugs (e.g. proquazone) into the parietal cells deep in the gastric mucosa (Brune, Graf & Rainsford 1977 , Brune, Schweitzer & Eckert 1977 .
Damage to the gastric mucosa by aspirin is more extensive at lower (pH 1.4) than at higher pH (e.g. pH 5.3) (Harding & Morris 1976) . Also, sloughing and disruption of the surface mucus layer by aspirin or salicylate occurs only at acidic but not at neutral pH conditions (Rainsford et al. 1968 ). The disruption of the mucus layer may be due to the physical interaction between the aspirin and acidic groups on mucus glycoproteins which would occur by means of hydrogen bonding only at low but not neutral pH (Rainsford 1977c) . Such physical interaction might be expected with other acidic NSAI drugs on penetration of the mucus layer.
For many acidic NSAI drugs that are readily absorbed by the gastric mucosa, it is the interaction of an acidic drug with acid-secreting areas of the stomach which is a prime factor in the development of gastric damage. The development of non-acidic NSAI drugs or acidic NSAI drugs with slow rates of absorption have been presented as obvious strategies for reducing gastric irritancy (Rainsford & Brune 1976 , Rainsford & Whitehouse 1976 , 1977 , Rainsford 1977c , Whitehouse & Rainsford 1977a . There are indications, however, that some of these strategies may not always result in adequate therapeutic activity being achieved (Rainsford & Whitehouse 1976 , 1977 , Rainsford 1977c , Whitehouse & Rainsford 1977a .
The pharmacokinetic concept of the action of acidic NSAI drugs, developed by Brune (1974) , presupposes that acidic drugs are selectively absorbed into the acidic sites in the body, including the stomach and inflamed tissues, and produce essentially non-specific effects (inhibition of oxidative metabolism, biosynthesis of mucopolysaccharides and prostaglandins, &c.) (Brune 1974 , Brune, Graf & Rainsford 1977 . Considerable evidence has now been obtained to support this pharmacokinetic concept as a principal factor in the development of therapeutic and side-effects of NSAI drugs (Graf et al. 1975 , Brune, Graf & Rainsford 1977 , Brune, Schweitzer & Eckert 1977 .
For therapeutic effects, the acidic NSAI drugs would be expected to be concentrated selectively in the acidic inflamed sites in accord with the principle that weakly acidic organic molecules will have a higher rate of absorption through lipid membranes when the site of uptake is under acidic compared with neutral pH conditions. As well, many of the NSAI drugs have a high degree of binding to plasma proteins so that, following the development of capillary damage and the increase in permeability that accompanies the inflammatory events, there will be an escape of protein-bound NSAI drug into the extravascular space and thus into the inflamed sites. Here dissociation of drug from its protein-bound form may occur through exposure to the lower pH at the site of inflammation. Clearly, these two son of the effects of a wide variety of NSAI drugs in this model of drug-induced gastric ulceration has been published elsewhere (Rainsford 1975b (Rainsford , 1977a . The results with established NSAI or analgesic drugs correlate with assessments of the clinical reports of the ulcerogenicity of these drugs, so illustrating the value of using this assay for predicting what may occur in the clinic (Rainsford 1977a) .
In the present studies the effects of fenclofenac (2-[2,4-dichlorophenoxy] phenylacetic acid) were studied using standard procedures in cold (45 min at -15°C) stressed rats (Rainsford 1977a ). The gastrointestinal mucosa was examined at 2, 4 and 6 hours after drug administration and concomitant exposures to stress conditions. The effects of fenclofenac were compared with aspirin (which is routinely employed as a standard in each day's assays to account for any day-to-day variation) and diclofenac sodium (Voltaren) which is a structurally similar drug (Table 1) . It should be noted that in comparing these drugs, the doses employed have been over a range to account for their varying potencies in the various models of inflammation (Atkinson & Leach 1976, Whitehouse & Rainsford, unpublished data) .
The data (Table 1) show that oral administration of fenclofenac to stressed (or non-stressed) rats resulted in the development of much less physicochemical properties (being weakly acidic organic molecules and possessing a high capacity for protein binding) are determinants of the action of what may be drugs with non-specific modes of action on cellular biochemical functions involved in inflammation. To develop non-acidic drugs (other than pre-drugs, e.g. see Sofia et al. 1975) appears to be an unsatisfactory strategy since this would not seem to be a way of achieving one feature of the specificity of therapeutic activity of NSAI drugs; a contradiction in purpose! Thus possible strategies for reducing gastric irritancy while at the same time maintaining therapeutic activity involve the development of (1) latent (or pre-) drugs, namely drugs which when metabolised yield the active form of the drug, or (2) potent NSAI drugs which specifically have a slow rate of uptake or minimal interaction with the acidic parietal cell components or other tissues in the stomach. This latter property may be shared by fenclofenac, a drug with very low gastric irritant potential.
Studies with Fenclofenac
The stress-sensitized rat model of NSAI-druginduced gastric ulcerogenesis affords a sensitive and rapid method for testing the likelihood of new drugs being ulcerogenic. A detailed compari- All drugs were administered orally unless otherwise stated as suspensions or solutions (prepared in 1 ml H,O) to starved (24 h) male or female rats which were subsequently stressed by exposure to cold (-15°C) for 45 min. The animals were killed 2 h later (except 0 which were killed at 6 h). The number of lesions, average severity of the lesions (graded on an arbitrary scale of 0 to 3 +) and number of animals with lesions were recorded and the sum of these three measurements obtained which comprises the lesion index (Rainsford 1975c ).
The degree of gastric swelling and mucus discharge (both graded on an arbitrary scale of 0 to 3 +) were also noted (Rainsford 1975b) as these effects represent responses of the stomach to presence of irritants. No sex differences were observed in the responses. Data from 5 animals per group. No lesions were observed in control animals exposed to stress alone 7 Fenclofenac at SAGE Publications on June 21, 2016 jrs.sagepub.com Downloaded from Table 2 Gastric mucosal damage following chronic oral administration of fenclofenac or aspirin to adjuvant arthritic and normal (non-stressed) rats The drugs were given orally (as 1.0 ml fine suspensions prepared in H20 immediately before use) for 10 days at doses of 200 mg/kg body weight/day to adjuvant arthritic or normal healthy female rats. The control animals received 1.0 ml H.O alone. The animals were starved of food and allowed water ad lib. for 24 h before termination of the experiment and were given a final dose of the drug 2 h before killing. The number of lesions, average severity of the lesions (graded on an arbitrary scale of 0 to 3 +) and number of animals with gastric lesions were recorded (Rainsford 1975c ). The sum of these three measurements represents the lesion index (Rainsford 1975c) . The degree of gastric swelling and mucus discharged (both graded on an arbitrary scale of 0 to 3 +) were also determined (Rainsfora 1975b) as indices of the action of locally applied irritants. Data are from 5 animals per group.
gastric mucosal damage than observed with either aspirin or diclofenac sodium under the same conditions. Likewise chronic oral administration of fenclofenac to normal rats and those with adjuvantinduced arthritis resulted in much less damage than induced by aspirin or diclofenac (Table 2) . These results show that in both physically and 'disease' stressed animals fenclofenac has low gastric irritancy. No signs of mucosal damage were observed in the intestinal mucosa of animals given single or repeated doses of fenclofenac.
Studies of the comparative effects of NSAI drugs have also been performed in pigs. Pigs have gastrointestinal physiology and anatomy which closely resembles that of humans (Bustad & McClellan 1966) . This species also develops gastric ulcers under conditions of psychophysiological stress akin to these effects in humans (Muggenburg et al. 1964 , Bustad & McClellan 1966 and so would seem admirably suited to the study of NSAI-drug-induced gastric ulcerogenesis.
The results of the comparative effects of fenclofenac, aspirin and diclofenac in pigs (Fig 1) show that fenclofenac did not produce any signs of gastric damage in starved (24 h) pigs, 2 h following a single oral dose (100 mg/kg) of the drug, whereas aspirin (100 mg/kg) and diclofenac (20 mg/kg) both produced extensive damage to the fundic mucosa (only) with associated hemorrhage.
For strict comparison of the chemical structure of diclofenac (sodium) with fenclofenac it is necessary to compare the sodium salts and parent acids of both drugs because the sodium salts would be expected to have greater solubility than the acids. Hence the effects on the gastric mucosa of fenclofenac sodium (prepared as an equimolar mixture of the drug with sodium bicarbonate) were compared with those of the sodium salt of diclofenac in rats. The results (Table l) show that the sodium salt of fenclofenac caused only a small increase in the gastric damage compared with the corresponding acid. Diclofenac as the acid has slightly less ulcerogenic capacity when compared to its sodium salt (Rainsford & Whitehouse, unpublished studies) . By comparison aspirin as the sodium salt is less ulcerogenic than aspirin (acid) (Rainsford 1975c (Rainsford , 1977c .
It is interesting to note the differences in solubility of the two sodium salts. Diclofenac sodium is very soluble in water whereas fenclofenac in sodium bicarbonate is only slightly soluble. These differences in solubility would seem to be important considerations in determining the relative gastric irritant or ulcerogenic capacities of these drugs. This is due to the faster rate of absorption in the stomach of NSAI drugs with higher aqueous solubility. For this reason studies were performed to determine whether there is an increased ulcerogenic capacity of fenclofenac when it is administered orally in a lipid soluble form (in organic solvents) or in a more bioavailable form by i.p. injection. In this way it should be possible to determine if fenclofenac is intrinsically less ulcerogenic (i.e. following penetration in the gastric mucosa) or whether solubility and hence penetration is a major factor.
The results (Table 1) show that marked increase in gastric mucosal damage was observed when fenclofenac was administered orally to stresssensitized rats as a mixture dissolved in organic solvents such as dimethylsulphoxide (DMSO), FI< 4>K( 1IJ (0) with 100 mg/kgfenclofenac or aspirin, or 20 mg/kg diclofenac ( Voltaren) allgiven asfine suspensions in 50 ml H20. Control animals were given 50 ml H20 alone. Two hours after drug administration the animals were killed and the gastrointestinal tract examinedfor mucosal damage. Few or no signs ofdamage were observed in the gastric mucosa ofanimals given fenclofenac but severe damage wuls observed after diclofenac and aspirin dimethyl formamide (DMF) or 70% v/v ethanol enhance the development of gastric mucosal to increase absorption of the drug into the gastric damage. It appears, therefore, that the low gastric mucosa. Also, intraperitoneal administration of irritancy of fenclofenac compared with other 100 mg/kg fenclofenac to stress-sensitized rats similar NSAI drugs may be due in part to the caused the development of gastric mucosal lower aqueous solubility of this drug. Caution damage not evident in control animals exposed to should, however, be observed in the interpretation stress alone. By comparison aspirin as the of the results obtained with fenclofenac dissolved sodium salt given intraperitoneally to stressed rats in the organic solvents since DMSO, DMF (Table  causes extensive gastric mucosal damage which is 1) and alcohol potentiate gastric damage from not evident in non-stressed animals (Rainsford exposure to stress (Kawashima & Glass 1975 ) or 1976 . NSAI drugs alone. However, the results do show These results show that increasing the mucosal that, as with aspirin and possibly other NSAI (or systemic) absorption of fenclofenac does drugs, the combination of fenclofenac and alcohol can be potentially ulcerogenic. In clinical practice, therefore, patients should be advised against taking alcohol and NSAI drugs including fenclofenac to minimize the possibility of gastric mucosal damage occurring.
Summary
The gastric irritant potential of fenclofenac was studied using a sensitive assay of gastric ulceration which has been developed in laboratory animals. The method employed is that the drug is given orally to rats which have been exposed to a brief period of physical (cold) stress. This procedure markedly increases the sensitivity of the gastric mucosa to damage by known ulcerogenic anti-inflammatory drugs (e.g. aspirin or indomethacin) but not non-ulcerogenic analgesic drugs (e.g. paracetamol). Fenclofenac (a phenoxyphenylacetic acid) was of relatively low irritancy in this assay whereas diclofenac (a structurally similar anilino-phenylacetic acid) was very ulcerogenic. Similar results were obtained from oral administration of these drugs to pigs, a species with a 'pseudo-human' stomach.
To establish if differences in mucosal absorption may contribute to these marked differences in ulcerogenic potential of these two drugs the gastric irritant effects were studied of fenclofenac dissolved in organic solventsdimethyl formamide, dimethylsulphoxide or alcohol (70% ethanol) -deliberately to enhance mucosal absorption of this relatively water-insoluble drug, diclofenac (Na salt) being relatively more soluble in water. The results show that enhancing the absorption of fenclofenac does increase the gastric irritant potential of this drug. It appears, therefore that the lower aqueous solubility of fenclofenac may account in part for the lower gastric irritancy of this drug compared with diclofenac.
